GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Download Free Sample Pages @ Leading players in the neurostimulation devices market include Medtronic, Boston Scientific, Abbott, LivaNova, NEVRO ... Vagus nerve stimulation remains a powerful ...

Leading players in the neurostimulation devices market include Medtronic, Boston Scientific, Abbott, LivaNova, NEVRO, and BrainsWay ... designs for treatment-resistant depression. Vagus nerve ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Nevro NVRO is well-poised for growth in the ... However, concerns regarding softness in the spinal cord stimulation (SCS) market and dependence on third-party payers persist.

Jan. 22, 2015 /PRNewswire/ -- Nevro Corp. (NYSE ... for the Senza spinal cord stimulation (SCS) system. According to the approvable letter, approval of the PMA is subject to satisfaction ...

Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS ...